The purpose of this study is to assess the effect of B. infantis (EVC001) versus placebo
supplementation, in healthy breastfed infants at risk of developing atopic dermatitis (AD),
on cumulative incidence of physician-diagnosed AD during the first year of life.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.